Menu utilisateur

Accès à distance ? S'identifier sur le proxy UCLouvain

The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation

Onglets principaux

Hesselink, Dennis A. Bouamar, Rachida Elens, Laure [UCL] Van Schaik, Ron H. N. Van Gelder, Teun

The calcineurin inhibitor tacrolimus is the backbone of immunosuppressive drug therapy after solid organ transplantation. Tacrolimus is effective in preventing acute rejection but has considerable toxicity and displays marked inter-individual variability in its pharmacokinetics and pharmacodynamics. The genetic basis of these phenomena is reviewed here. With regard to its pharmacokinetic variability, a single nucleotide polymorphism (SNP) in cytochrome P450 (CYP) 3A5 (6986A>G) has been consistently associated with tacrolimus dose requirement. Patients expressing CYP3A5 (those carrying the A nucleotide, defined as the 1 allele) have a dose requirement that is around 50 % higher than non-expressers (those homozygous for the G nucleotide, defined as the 3 allele). A randomised controlled study in kidney transplant recipients has demonstrated that a CYP3A5 genotype-based approach to tacrolimus dosing leads to more patients reaching the target concentration early after transplantation. However, no improvement of clinical outcomes (rejection incidence, toxicity) was observed, which may have been the result of the design of this particular study. In addition to CYP3A5 genotype, other genetic variants may also contribute to the variability in tacrolimus pharmacokinetics. Among these, the CYP3A4 22 and POR 28 SNPs are the most promising. Individuals carrying the CYP3A422 T-variant allele have a lower tacrolimus dose requirement than individuals with the CYP3A422 CC genotype and this effect appears to be independent of CYP3A5 genotype status. Individuals carrying the POR28 T-variant allele have a higher tacrolimus dose requirement than POR28 CC homozygotes but this association was only found in CYP3A5-expressing individuals. Other, less well-defined SNPs have been inconsistently associated with tacrolimus dose requirement. It is envisaged that in the future, algorithms incorporating clinical, demographic and genetic variables will be developed that will aid clinicians with the determination of the tacrolimus starting dose for an individual transplant recipient. Such an approach may limit early tacrolimus under-exposure and toxicity. With regard to tacrolimus pharmacodynamics, no strong genotype-phenotype relationships have been identified. Certain SNPs associate with rejection risk but these observations await replication. Likewise, the genetic basis of tacrolimus-induced toxicity remains unclarified. SNPs in the genes encoding for the drug transporter ABCB1 and the CYP3A enzymes may relate to chronic nephrotoxicity but findings have been inconsistent. No genetic markers reliably predict new-onset diabetes mellitus after transplantation, hypertension or neurotoxicity. The CYP3A51 SNP is currently the most promising biomarker for tailoring tacrolimus treatment. However, before CYP3A5 genotyping is incorporated into the routine clinical care of transplant recipients, prospective clinical trials are needed to determine whether such a strategy improves patient outcomes. The role of pharmacogenetics in tacrolimus pharmacodynamics should be explored further by the study of intra-lymphocyte and tissue tacrolimus concentrations. © 2013 Springer International Publishing Switzerland.

Type de document Article de périodique (Journal article) – Synthèse de littérature
Année de publication 2014
Langue Anglais
Information sur le périodique "Clinical Pharmacokinetics" - Vol. 53, no. 2, p. 123-139 (2014)
Peer reviewed oui
Editeur Adis International Ltd. ((New Zealand) Auckland)
issn 0312-5963
e-issn 1179-1926
Statut de la publication Publié
Affiliations UCL - SSS/LDRI - Louvain Drug Research Institute
Liens
  1. Kaufman Dixon B., Shapiro Ron, Lucey Michael R., Cherikh Wida S., T. Bustami Rami, Dyke David B., Immunosuppression: practice and trends : Immunosuppression, 10.1111/j.1600-6135.2004.00397.x
  2. Matas A. J., Smith J. M., Skeans M. A., Lamb K. E., Gustafson S. K., Samana C. J., Stewart D. E., Snyder J. J., Israni A. K., Kasiske B. L., OPTN/SRTR 2011 Annual Data Report: Kidney, 10.1111/ajt.12019
  3. Wallemacq Pierre, Armstrong Victor W, Brunet Merce, Haufroid Vincent, Holt David W, Johnston Atholl, Kuypers Dirk, Meur Yannick Le, Marquet Pierre, Oellerich Michael, Thervet Eric, Toenshoff Burkhand, Undre Nas, Weber Lutz T, Westley Ian S, Mourad Michel, Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference : , 10.1097/ftd.0b013e318198d092
  4. Venkataramanan Raman, Swaminathan Arun, Prasad Tata, Jain Ashok, Zuckerman Sheila, Warty Vijay, McMichael John, Lever Jacqueline, Burckart Gilbert, Starzl Thomas, Clinical Pharmacokinetics of Tacrolimus : , 10.2165/00003088-199529060-00003
  5. Christians Uwe, Jacobsen Wolfgang, Benet Leslie Z., Lampen Alfonso, Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus : , 10.2165/00003088-200241110-00003
  6. Staatz Christine E, Tett Susan E, Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation : , 10.2165/00003088-200443100-00001
  7. van Maarseveen Erik M., Rogers Christin C., Trofe-Clark Jennifer, van Zuilen Arjan D., Mudrikova Tania, Drug–Drug Interactions Between Antiretroviral and Immunosuppressive Agents in HIV-Infected Patients After Solid Organ Transplantation: A Review, 10.1089/apc.2012.0169
  8. Staatz Christine E., Goodman Lucy K., Tett Susan E., Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I : , 10.2165/11317350-000000000-00000
  9. Staatz Christine E., Goodman Lucy K., Tett Susan E., Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part II : , 10.2165/11317550-000000000-00000
  10. MacPhee Iain A.M., Pharmacogenetic biomarkers: cytochrome P450 3A5, 10.1016/j.cca.2011.10.013
  11. Elens Laure, Hesselink Dennis A., van Schaik Ron H. N., van Gelder Teun, Pharmacogenetics in Kidney Transplantation : Recent Updates and Potential Clinical Applications, 10.1007/s40291-012-0012-5
  12. Zhang Yuanchao, Benet Leslie Z., The Gut as a Barrier to Drug Absorption : Combined Role of Cytochrome P450 3A and P-Glycoprotein, 10.2165/00003088-200140030-00002
  13. Klimecki WT, Futscher BW, Grogan TM, et al. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood. 1994;83:2451–8.
  14. Kamdem L. K., Contribution of CYP3A5 to the in Vitro Hepatic Clearance of Tacrolimus, 10.1373/clinchem.2005.050047
  15. Dai Yang, Iwanaga Kazunori, Lin Yvonne S., Hebert Mary F., Davis Connie L., Huang Weili, Kharasch Evan D., Thummel Kenneth E., In vitro metabolism of cyclosporine A by human kidney CYP3A5, 10.1016/j.bcp.2004.07.012
  16. Dai Y., EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRO, 10.1124/dmd.105.008680
  17. Möller A, Iwasaki K, Kawamura A, et al. The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab Dispos. 1999;27:633–6.
  18. Thiebaut F., Tsuruo T., Hamada H., Gottesman M. M., Pastan I., Willingham M. C., Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues., 10.1073/pnas.84.21.7735
  19. Murray G I, McFadyen M C E, Mitchell R T, Cheung Y-L, Kerr A C, Melvin W T, Cytochrome P450 CYP3A in human renal cell cancer, 10.1038/sj.bjc.6690292
  20. Koch I., Interindividual Variability and Tissue-Specificity in the Expression of Cytochrome P450 3A mRNA, 10.1124/dmd.30.10.1108
  21. Benkali Khaled, Rostaing Lionel, Premaud Aurélie, Woillard Jean-Baptiste, Saint-Marcoux Franck, Urien Saik, Kamar Nassim, Marquet Pierre, Rousseau Annick, Population Pharmacokinetics and Bayesian Estimation of Tacrolimus Exposure in Renal Transplant Recipients on a New Once-Daily Formulation : , 10.2165/11535950-000000000-00000
  22. Hougardy Jean-Michel, de Jonge Hylke, Kuypers Dirk, Abramowicz Daniel, The Once-Daily Formulation of Tacrolimus : A Step Forward in Kidney Transplantation?, 10.1097/tp.0b013e31823aa56e
  23. Kuehl Peter, Zhang Jiong, Lin Yvonne, Lamba Jatinder, Assem Mahfoud, Schuetz John, Watkins Paul B., Daly Ann, Wrighton Steven A., Hall Stephen D., Maurel Patrick, Relling Mary, Brimer Cynthia, Yasuda Kazuto, Venkataramanan Raman, Strom Stephen, Thummel Kenneth, Boguski Mark S., Schuetz Erin, 10.1038/86882
  24. CYP3A5 allele nomenclature. http://www.cypalleles.ki.se/cyp3a5.htm . Accessed 28 Oct 2013.
  25. Hustert Elisabeth, Haberl Michael, Burk Oliver, Wolbold Renzo, He You-Qun, Klein Kathrin, Nuessler Andreas C., Neuhaus Peter, Klattig Jürgen, Eiselt Regina, Koch Ina, Zibat Arne, Brockmöller Jürgen, Halpert James R., Zanger Ulrich M., Wojnowski Leszek, The genetic determinants of the CYP3A5 polymorphism : , 10.1097/00008571-200112000-00005
  26. van Schaik RHN, van der Heiden IP, van den Anker JN, et al. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem. 2002;48:1668–71.
  27. Hesselink D, Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus, 10.1016/s0009-9236(03)00168-1
  28. Thervet Eric, Anglicheau Dany, King Barry, Schlageter Marie-H??l??ne, Cassinat Bruno, Beaune Philippe, Legendre Christophe, Daly Ann K., Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12 : , 10.1097/01.tp.0000090753.99170.89
  29. Haufroid Vincent, Mourad Michel, Van Kerckhove Val??rie, Wawrzyniak Jeremie, De Meyer Martine, Eddour Djamila Chaib, Malaise Jacques, Lison Dominique, Squifflet Jean-Paul, Wallemacq Pierre, The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients : , 10.1097/00008571-200403000-00002
  30. Tsuchiya Norihiko, Satoh Shigeru, Tada Hitoshi, Li Zhenhua, Ohyama Chikara, Sato Kazunari, Suzuki Toshio, Habuchi Tomonori, Kato Tetsuro, Influence of CYP3A5 and MDR1 (ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients : , 10.1097/01.tp.0000137789.58694.b4
  31. MacPhee Iain A.M., Fredericks Salim, Mohamed Maha, Moreton Michelle, Carter Nicholas D., Johnston Atholl, Goldberg Lawrence, Holt David W., Tacrolimus Pharmacogenetics: The CYP3A5*1 Allele Predicts Low Dose-Normalized Tacrolimus Blood Concentrations in Whites and South Asians : , 10.1097/01.tp.0000151766.73249.12
  32. Zhang Xin, Liu Zhi-hong, Zheng Jing-min, Chen Zhao-hong, Tang Zheng, Chen Jin-song, Li Lei-shi, Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation, 10.1111/j.1399-0012.2005.00370.x
  33. Zhao Y., Song M., Guan D., Bi S., Meng J., Li Q., Wang W., Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus, 10.1016/j.transproceed.2005.01.077
  34. Haufroid V., Wallemacq P., VanKerckhove V., Elens L., De Meyer M., Eddour D. C., Malaise J., Lison D., Mourad M., CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental Study, 10.1111/j.1600-6143.2006.01518.x
  35. Roy Jean Nicholas, Barama Azemi, Poirier Charles, Vinet Bernard, Roger Michel, Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients : , 10.1097/01.fpc.0000220571.20961.dd
  36. Renders L, Frisman M, Ufer M, Mosyagin I, Haenisch S, Ott U, Caliebe A, Dechant M, Braun F, Kunzendorf U, Cascorbi I, CYP3A5 Genotype Markedly Influences the Pharmacokinetics of Tacrolimus and Sirolimus in Kidney Transplant Recipients, 10.1038/sj.clpt.6100039
  37. Rong G., Jing L., Deng-Qing L., Hong-Shan Z., Shai-Hong Z., Xin-Min N., Influence of CYP3A5 and MDR1(ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Chinese Renal Transplant Recipients, 10.1016/j.transproceed.2010.08.063
  38. Santoro Ana, Felipe Claudia R, Tedesco-Silva Helio, Medina-Pestana Jose O, Struchiner Claudio J, Ojopi Elida B, Suarez-Kurtz Guilherme, Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients, 10.2217/pgs.11.70
  39. Glowacki François, Lionet Arnaud, Buob David, Labalette Myriam, Allorge Delphine, Provôt François, Hazzan Marc, Noël Christian, Broly Franck, Cauffiez Christelle, CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation, 10.1093/ndt/gfr253
  40. Gervasini Guillermo, Garcia Montserrat, Macias Rosa María, Cubero Juan Jose, Caravaca Francisco, Benitez Julio, Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation : Pharmacogenetics of tacrolimus, 10.1111/j.1432-2277.2012.01446.x
  41. Ferraresso Mariano, Tirelli Amedea, Ghio Luciana, Grillo Paolo, Martina Valentina, Torresani Erminio, Edefonti Alberto, Influence of the Cyp3a5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients, 10.1111/j.1399-3046.2006.00662.x
  42. Zhao W, Elie V, Roussey G, Brochard K, Niaudet P, Leroy V, Loirat C, Cochat P, Cloarec S, André J L, Garaix F, Bensman A, Fakhoury M, Jacqz-Aigrain E, Population Pharmacokinetics and Pharmacogenetics of Tacrolimus in De Novo Pediatric Kidney Transplant Recipients, 10.1038/clpt.2009.210
  43. Elmachad Mustapha, Elkabbaj Driss, Elkerch Fatiha, Laarabi Fatima Zahra, Barkat Amina, Oualim Zouhir, Sefiani Abdelaziz, Frequencies ofCYP3A5*1/*3Variants in a Moroccan Population and Effect on Tacrolimus Daily Dose Requirements in Renal Transplant Patients, 10.1089/gtmb.2011.0240
  44. García-Roca Pilar, Medeiros Mara, Reyes Herlinda, Rodríguez-Espino Benjamín Antonio, Alberú Josefina, Ortiz Lourdes, Vásquez-Perdomo Mayela, Elizondo Guillermo, Morales-Buenrostro Luis Eduardo, Mancilla Urrea Eduardo, Castañeda-Hernández Gilberto, CYP3A5 Polymorphism in Mexican Renal Transplant Recipients and its Association with Tacrolimus Dosing, 10.1016/j.arcmed.2012.05.005
  45. Zheng HongXia, Webber Steven, Zeevi Adriana, Schuetz Erin, Zhang Jiong, Bowman Pamela, Boyle Gerard, Law Yuk, Miller Susan, Lamba Jatinder, Burckart Gilbert J., Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms, 10.1034/j.1600-6143.2003.00077.x
  46. Zheng HongXia, Zeevi Adriana, Schuetz Erin, Lamba Jatinder, McCurry Kenneth, Griffith Bartley P., Webber Steven, Ristich Julianne, Dauber James, Iacono Aldo, Grgurich Wayne, Zaldonis Diana, McDade Kevin, Zhang Jiong, Burckart Gilbert J., Tacrolimus Dosing in Adult Lung Transplant Patients Is Related to Cytochrome P4503A5 Gene Polymorphism, 10.1177/0091270003262108
  47. Goto Maki, Masuda Satohiro, Kiuchi Tetsuya, Ogura Yasuhiro, Oike Fumitaka, Okuda Masahiro, Tanaka Koichi, Inui Ken-ichi, CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation : , 10.1097/01.fpc.0000114747.08559.49
  48. Fukudo Masahide, Yano Ikuko, Yoshimura Atsushi, Masuda Satohiro, Uesugi Miwa, Hosohata Keiko, Katsura Toshiya, Ogura Yasuhiro, Oike Fumitaka, Takada Yasutsugu, Uemoto Shinji, Inui Ken-ichi, Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients : , 10.1097/fpc.0b013e3282f9ac01
  49. Kniepeiss Daniela, Renner Wilfried, Trummer Olivia, Wagner Doris, Wasler Andrä, Khoschsorur Gholam A., Truschnig-Wilders Martie, Tscheliessnigg Karl-Heinz, The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation : CYP3A5 and dosing of tacrolimus and everolimus, 10.1111/j.1399-0012.2009.01198.x
  50. Gijsen Violette, Mital Seema, van Schaik Ron H., Soldin Offie P., Soldin Steven J., van der Heiden Ilse P., Nulman Irena, Koren Gideon, de Wildt Saskia N., Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients, 10.1016/j.healun.2011.08.001
  51. Tang Hui-Lin, Xie Hong-Guang, Yao Yao, Hu Yong-Fang, Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers : , 10.1097/fpc.0b013e32834a48ca
  52. Terrazzino Salvatore, Quaglia Marco, Stratta Piero, Canonico Pier L., Genazzani Armando A., The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients : a systematic review and meta-analysis, 10.1097/fpc.0b013e3283557c74
  53. Birdwell Kelly A., Grady Ben, Choi Leena, Xu Hua, Bian Aihua, Denny Josh C., Jiang Min, Vranic Gayle, Basford Melissa, Cowan James D., Richardson Danielle M., Robinson Melanie P., Ikizler Talat Alp, Ritchie Marylyn D., Stein Charles Michael, Haas David W., The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients : , 10.1097/fpc.0b013e32834e1641
  54. Andrews Peter A, Sen Manoj, Chang René WS, Racial variation in dosage requirements of tacrolimus, 10.1016/s0140-6736(04)70087-2
  55. Mancinelli L, The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups, 10.1067/mcp.2001.113183
  56. Jacobson Pamala A., Oetting William S., Brearley Ann M., Leduc Robert, Guan Weihau, Schladt David, Matas Arthur J., Lamba Vishal, Julian Bruce A., Mannon Rosalyn B., Israni Ajay, Novel Polymorphisms Associated With Tacrolimus Trough Concentrations: Results From a Multicenter Kidney Transplant Consortium : , 10.1097/tp.0b013e318200e991
  57. Passey Chaitali, Birnbaum Angela K., Brundage Richard C., Oetting William S., Israni Ajay K., Jacobson Pamala A., Dosing equation for tacrolimus using genetic variants and clinical factors : Tacrolimus dosing equation, 10.1111/j.1365-2125.2011.04039.x
  58. Passey Chaitali, Birnbaum Angela K, Brundage Richard C, Schladt David P, Oetting William S, Leduc Robert E, Israni Ajay K, Guan Weihua, Matas Arthur J, Jacobson Pamala A, Validation of tacrolimus equation to predict troughs using genetic and clinical factors, 10.2217/pgs.12.98
  59. PharmGKB. Dutch Pharmacogenetics Working Group guideline for tacrolimus and CYP3A5. http://www.pharmgkb.org/gene/PA131 . Accessed 28 Oct 2013.
  60. Lamba Jatinder, Hebert Joan M., Schuetz Erin G., Klein Teri E., Altman Russ B., PharmGKB summary : very important pharmacogene information for CYP3A5, 10.1097/fpc.0b013e328351d47f
  61. Wehland M, Bauer S, Brakemeier S, et al. Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations. Pharmacogenet Genom. 2011;21:179–84.
  62. Glowacki François, Lionet Arnaud, Hammelin Jean-Philippe, Labalette Myriam, Provôt François, Hazzan Marc, Broly Franck, Noël Christian, Cauffiez Christelle, Influence of Cytochrome P450 3A5 (CYP3A5) Genetic Polymorphism on the Pharmacokinetics of the Prolonged-Release, Once-Daily Formulation of Tacrolimus in Stable Renal Transplant Recipients : , 10.2165/11587050-000000000-00000
  63. Niioka Takenori, Satoh Shigeru, Kagaya Hideaki, Numakura Kazuyuki, Inoue Takamitsu, Saito Mitsuru, Narita Shintaro, Tsuchiya Norihiko, Habuchi Tomonori, Miura Masatomo, Comparison of Pharmacokinetics and Pharmacogenetics of Once- and Twice-Daily Tacrolimus in the Early Stage After Renal Transplantation : , 10.1097/tp.0b013e31826bc400
  64. Niioka Takenori, Kagaya Hideaki, Miura Masatomo, Numakura Kazuyuki, Saito Mitsuru, Inoue Takamitsu, Habuchi Tomonori, Satoh Shigeru, Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients, 10.1007/s00228-013-1514-8
  65. Zhao Wei, Fakhoury May, Baudouin Véronique, Storme Thomas, Maisin Anne, Deschênes Georges, Jacqz-Aigrain Evelyne, Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients, 10.1007/s00228-012-1330-6
  66. MacPhee Iain A. M., Fredericks Salim, Tai Tracy, Syrris Petros, Carter Nicholas D., Johnston Atholl, Goldberg Lawrence, Holt David W., The Influence of Pharmacogenetics on the Time to Achieve Target Tacrolimus Concentrations after Kidney Transplantation, 10.1111/j.1600-6143.2004.00435.x
  67. Hesselink Dennis A., van Schaik Ron H.N., van Agteren Madelon, de Fijter Johannes W., Hartmann Anders, Zeier Martin, Budde Klemens, Kuypers Dirk R.J., Pisarski Przemyslav, Meur Yann Le, Mamelok Richard D., van Gelder Teun, CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients : , 10.1097/fpc.0b013e3282f75f88
  68. Kuypers D R J, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y, CYP3A5 and CYP3A4 but not MDR1 Single-nucleotide Polymorphisms Determine Long-term Tacrolimus Disposition and Drug-related Nephrotoxicity in Renal Recipients, 10.1038/sj.clpt.6100216
  69. Thervet E, Loriot MA, Barbier S, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther. 2010;87:721–6.
  70. van Gelder T, Hesselink D A, Dosing Tacrolimus Based on CYP3A5 Genotype: Will It Improve Clinical Outcome?, 10.1038/clpt.2010.42
  71. Nederlands Trial Register. http://www.trialregister.nl/trialreg/index.asp . Accessed 28 Oct 2013.
  72. ClinicalTrials.gov. http://www.clinicaltrials.gov/ . Accessed 28 Oct 2013.
  73. Kuypers D R J, Pharmacogenetic vs. Concentration-Controlled Optimization of Tacrolimus Dosing in Renal Allograft Recipients, 10.1038/clpt.2010.129
  74. Bouamar R., Shuker N., Hesselink D. A., Weimar W., Ekberg H., Kaplan B., Bernasconi C., van Gelder T., Tacrolimus Predose Concentrations Do Not Predict the Risk of Acute Rejection After Renal Transplantation: A Pooled Analysis From Three Randomized-Controlled Clinical Trials† : Tacrolimus Concentrations and Acute Rejection, 10.1111/ajt.12191
  75. Hoffmeyer S., Burk O., von Richter O., Arnold H. P., Brockmoller J., Johne A., Cascorbi I., Gerloff T., Roots I., Eichelbaum M., Brinkmann U., Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo, 10.1073/pnas.97.7.3473
  76. Wang Danxin, Johnson Andrew D., Papp Audrey C., Kroetz Deanna L., Sadée Wolfgang, Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability : , 10.1097/01.fpc.0000178311.02878.83
  77. Kimchi-Sarfaty C., Oh J. M., Kim I.-W., Sauna Z. E., Calcagno A. M., Ambudkar S. V., Gottesman M. M., A "Silent" Polymorphism in the MDR1 Gene Changes Substrate Specificity, 10.1126/science.1135308
  78. Shuker Nauras, Bouamar Rachida, Weimar Willem, van Schaik Ron.H.N., van Gelder Teun, Hesselink Dennis A., ATP-binding cassette transporters as pharmacogenetic biomarkers for kidney transplantation, 10.1016/j.cca.2011.09.040
  79. Wang D, Guo Y, Wrighton S A, Cooke G E, Sadee W, Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs, 10.1038/tpj.2010.28
  80. Elens Laure, Becker Matthijs L., Haufroid Vincent, Hofman Albert, Visser Loes E., Uitterlinden André G., Stricker Bruno Ch., van Schaik Ron H.N., Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study : , 10.1097/fpc.0b013e32834c6edb
  81. Elens L., Bouamar R., Hesselink D. A., Haufroid V., van der Heiden I. P., van Gelder T., van Schaik R. H. N., A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients, 10.1373/clinchem.2011.165613
  82. Elens Laure, van Schaik Ron H, Panin Nadtha, de Meyer Martine, Wallemacq Pierre, Lison Dominique, Mourad Michel, Haufroid Vincent, Effect of a new functionalCYP3A4polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients, 10.2217/pgs.11.90
  83. Gijsen Violette MGJ, van Schaik Ron HN, Elens Laure, Soldin Offie P, Soldin Steven J, Koren Gideon, de Wildt Saskia N, CYP3A4*22andCYP3Acombined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients, 10.2217/pgs.13.80
  84. Elens Laure, Hesselink Dennis A., van Schaik Ron H. N., van Gelder Teun, TheCYP3A4*22allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations : Letter to the Editors, 10.1111/bcp.12038
  85. Santoro A B, Struchiner C J, Felipe C R, Tedesco-Silva H, Medina-Pestana J O, Suarez-Kurtz G, CYP3A5 Genotype, but Not CYP3A4*1b, CYP3A4*22, or Hematocrit, Predicts Tacrolimus Dose Requirements in Brazilian Renal Transplant Patients, 10.1038/clpt.2013.68
  86. Tavira Beatriz, Coto Eliecer, Diaz-Corte Carmen, Alvarez Victoria, López-Larrea Carlos, Ortega Francisco, A search for new CYP3A4 variants as determinants of tacrolimus dose requirements in renal-transplanted patients : , 10.1097/fpc.0b013e3283636856
  87. Hart Steven N, Zhong Xiao-bo, P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity, 10.1517/17425255.4.4.439
  88. Huang N., Agrawal V., Giacomini K. M., Miller W. L., Genetics of P450 oxidoreductase: Sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations, 10.1073/pnas.0711621105
  89. de Jonge Hylke, Metalidis Christoph, Naesens Maarten, Lambrechts Diether, Kuypers Dirk RJ, The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients, 10.2217/pgs.11.77
  90. Elens Laure, Hesselink Dennis A., Bouamar Rachida, Budde Klemens, de Fijter Johannes W., De Meyer Martine, Mourad Michel, Kuypers Dirk R. J., Haufroid Vincent, van Gelder Teun, van Schaik Ron H. N., Impact of POR*28 on the Pharmacokinetics of Tacrolimus and Cyclosporine a in Renal Transplant Patients : , 10.1097/ftd.0b013e31829da6dd
  91. Zhang Jing-Jing, Zhang Hua, Ding Xiao-Liang, Ma Sheng, Miao Li-Yan, Effect of the P450 oxidoreductase *28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers, 10.1007/s00228-012-1432-1
  92. Miura Masatomo, Satoh Shigeru, Inoue Kazuyuki, Kagaya Hideaki, Saito Mitsuru, Inoue Takamitsu, Habuchi Tomonori, Suzuki Toshio, Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients, 10.1016/j.steroids.2008.04.002
  93. Benkali Khaled, Prémaud Aurelie, Picard Nicolas, Rérolle Jean-Philippe, Toupance Olivier, Hoizey Guillaume, Turcant Alain, Villemain Florence, Le Meur Yannick, Marquet Pierre, Rousseau Annick, Tacrolimus Population Pharmacokinetic-Pharmacogenetic Analysis and Bayesian Estimation in Renal Transplant Recipients : , 10.2165/11318080-000000000-00000
  94. Press Rogier R, Ploeger Bart A, Hartigh Jan den, Straaten Tahar van der, Pelt Johannes van, Danhof Meindert, Fijter Johan W de, Guchelaar Henk-Jan, Explaining Variability in Tacrolimus Pharmacokinetics to Optimize Early Exposure in Adult Kidney Transplant Recipients : , 10.1097/ftd.0b013e31819c3d6d
  95. Barraclough Katherine A., Isbel Nicole M., Lee Katie J., Bergmann Troels K., Johnson David W., McWhinney Brett C., Ungerer Jacobus P. J., Campbell Scott B., Leary Diana R., Bialasiewicz Seweryn, Rockett Rebecca J., Staatz Christine E., NR1I2 Polymorphisms Are Related to Tacrolimus Dose-Adjusted Exposure and BK Viremia in Adult Kidney Transplantation : , 10.1097/tp.0b013e31826c3985
  96. Shi X.-J., Geng F., Jiao Z., Cui X.-Y., Qiu X.-Y., Zhong M.-K., Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis : Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the PK of tacrolimus, 10.1111/j.1365-2710.2010.01206.x
  97. Zuo Xiao-cong, Ng Chee M., Barrett Jeffrey S., Luo Ai-jing, Zhang Bi-kui, Deng Chen-hui, Xi Lan-yan, Cheng Ke, Ming Ying-zi, Yang Guo-ping, Pei Qi, Zhu Li-jun, Yuan Hong, Liao Hai-qiang, Ding Jun-jie, Wu Di, Zhou Ya-nan, Jing Ning-ning, Huang Zhi-jun, Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients : a population pharmacokinetic analysis, 10.1097/fpc.0b013e32835fcbb6
  98. Klein Kathrin, Thomas Maria, Winter Stefan, Nussler Andreas K., Niemi Mikko, Schwab Matthias, Zanger Ulrich M., PPARA: A Novel Genetic Determinant of CYP3A4 In Vitro and In Vivo, 10.1038/clpt.2011.336
  99. Boughton Oliver, Borgulya Gabor, Cecconi Maurizio, Fredericks Salim, Moreton-Clack Michelle, MacPhee Iain A. M., A published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an independent cohort of renal transplant recipients : Test of tacrolimus pharmacogenetic dosing algorithm, 10.1111/bcp.12076
  100. Halloran P.F., Kung L., Noujaim J., Calcineurin and the biological effect of cyclosporine and tacrolimus, 10.1016/s0041-1345(98)00577-6
  101. Grinyó Josep, Vanrenterghem Yves, Nashan Björn, Vincenti Flavio, Ekberg Henrik, Lindpaintner Klaus, Rashford Michelle, Nasmyth-Miller Clare, Voulgari Athina, Spleiss Olivia, Truman Matthew, Essioux Laurent, Association of four DNA polymorphisms with acute rejection after kidney transplantation, 10.1111/j.1432-2277.2008.00679.x
  102. Min Sang-Il, Kim Seong Yup, Ahn Sang Hyun, Min Seung-Kee, Kim Si Hwa, Kim Yon Su, Moon Kyung Chul, Oh Jung Mi, Kim Sang Joon, Ha Jongwon, CYP3A5 *1 Allele: Impacts on Early Acute Rejection and Graft Function in Tacrolimus-Based Renal Transplant Recipients : , 10.1097/tp.0b013e3181fa93a4
  103. Israni Ajay, Leduc Robert, Holmes John, Jacobson Pamala A., Lamba Vishal, Guan Weihua, Schladt David, Chen Jinbo, Matas Arthur J., Oetting William S., Single-Nucleotide Polymorphisms, Acute Rejection, and Severity of Tubulitis in Kidney Transplantation, Accounting for Center-to-Center Variation : , 10.1097/tp.0b013e3182000085
  104. Oetting William S., Schladt David P., Leduc Robert E., Jacobson Pamala A., Guan Weihua, Matas Arthur J., Israni Ajay, , Validation of single nucleotide polymorphisms associated with acute rejection in kidney transplant recipients using a large multi-center cohort : Validation of SNPs associated with AR, 10.1111/j.1432-2277.2011.01359.x
  105. Naesens M, Kuypers DRJ, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4:481–508.
  106. Hesselink Dennis A, Bouamar Rachida, van Gelder Teun, The Pharmacogenetics of Calcineurin Inhibitor–Related Nephrotoxicity : , 10.1097/ftd.0b013e3181e44244
  107. Jacobson Pamala A., Schladt David, Oetting William S., Leduc Robert, Guan Weihau, Matas Arthur J., Lamba Vishal, Mannon Roslyn B., Julian Bruce A., Israni Ajay, Reply to “Genetic Determinants of Mycophenolate-Related Anemia and Leukopenia After Transplantation” : , 10.1097/tp.0b013e3182529bdf
  108. Ojo Akinlolu O., Held Philip J., Port Friedrich K., Wolfe Robert A., Leichtman Alan B., Young Eric W., Arndorfer Julie, Christensen Laura, Merion Robert M., Chronic Renal Failure after Transplantation of a Nonrenal Organ, 10.1056/nejmoa021744
  109. Isnard Bagnis C., Long-Term Renal Effects of Low-Dose Cyclosporine in Uveitis-Treated Patients: Follow-Up Study, 10.1097/01.asn.0000034945.61533.26
  110. van Gelder T, Renal insufficiency after heart transplantation: a case-control study, 10.1093/ndt/13.9.2322
  111. Zheng S, Tasnif Y, Hebert M F, Davis C L, Shitara Y, Calamia J C, Lin Y S, Shen D D, Thummel K E, Measurement and Compartmental Modeling of the Effect of CYP3A5 Gene Variation on Systemic and Intrarenal Tacrolimus Disposition, 10.1038/clpt.2012.175
  112. Metalidis Christoph, Lerut Evelyne, Naesens Maarten, Kuypers Dirk R.J., Expression of CYP3A5 and P-glycoprotein in Renal Allografts With Histological Signs of Calcineurin Inhibitor Nephrotoxicity : , 10.1097/tp.0b013e3182177502
  113. Joy M. S., Hogan S. L., Thompson B. D., Finn W. F., Nickeleit V., Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity, 10.1093/ndt/gfm133
  114. Kuypers Dirk R J, Naesens Maarten, de Jonge Hylke, Lerut Evelyne, Verbeke Kristin, Vanrenterghem Yves, Tacrolimus Dose Requirements and CYP3A5 Genotype and the Development of Calcineurin Inhibitor-Associated Nephrotoxicity in Renal Allograft Recipients : , 10.1097/ftd.0b013e3181e06818
  115. Quteineh Lina, Verstuyft Céline, Furlan Valerie, Durrbach Antoine, Letierce Alexia, Ferlicot Sophie, Taburet Anne-Marie, Charpentier Bernard, Becquemont Laurent, Influence ofCYP3A5Genetic Polymorphism on Tacrolimus Daily Dose Requirements and Acute Rejection in Renal Graft Recipients, 10.1111/j.1742-7843.2008.00327.x
  116. Klauke Bärbel, Wirth Andreas, Zittermann Armin, Bohms Birte, Tenderich Gero, Körfer Reiner, Milting Hendrik, No Association Between Single Nucleotide Polymorphisms and the Development of Nephrotoxicity After Orthotopic Heart Transplantation, 10.1016/j.healun.2008.04.001
  117. Naesens M., Lerut E., de Jonge H., Van Damme B., Vanrenterghem Y., Kuypers D. R. J., Donor Age and Renal P-Glycoprotein Expression Associate with Chronic Histological Damage in Renal Allografts, 10.1681/asn.2009020192
  118. Joy Melanie S., Nickeleit Volker, Hogan Susan L., Thompson Bawana D., Finn William F., Calcineurin Inhibitor–Induced Nephrotoxicity and Renal Expression of P-glycoprotein, 10.1592/phco.2005.25.6.779
  119. Moore J., McKnight A. J., Dohler B., Simmonds M. J., Courtney A. E., Brand O. J., Briggs D., Ball S., Cockwell P., Patterson C. C., Maxwell A. P., Gough S. C. L., Opelz G., Borrows R., Donor ABCB1 Variant Associates with Increased Risk for Kidney Allograft Failure, 10.1681/asn.2012030260
  120. Woillard J-B, Rerolle J-P, Picard N, Rousseau A, Guillaudeau A, Munteanu E, Essig M, Drouet M, Le Meur Y, Marquet P, Donor P-gp Polymorphisms Strongly Influence Renal Function and Graft Loss in a Cohort of Renal Transplant Recipients on Cyclosporine Therapy in a Long-Term Follow-Up, 10.1038/clpt.2010.62
  121. Lemos Francine B. C., Mol Wendy M., Roodnat Joke I., Uitterlinden Andr??, IJzermans Jan N. M., Weimar Willem, Baan Carla C., The Beneficial Effects of Recipient-Derived Vascular Endothelial Growth Factor on Graft Survival after Kidney Transplantation : , 10.1097/01.tp.0000161219.75906.ec
  122. Moore Jason, Association of Caveolin-1 Gene Polymorphism With Kidney Transplant Fibrosis and Allograft Failure, 10.1001/jama.2010.356
  123. Smith Helen E., Jones J.P., Kalhorn Thomas F., Farin Federico M., Stapleton Patricia L., Davis Connie L., Perkins James D., Blough David K., Hebert Mary F., Thummel Kenneth E., Totah Rheem A., Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease : , 10.1097/fpc.0b013e32830e1e16
  124. van de Wetering Jacqueline, Weimar Charlotte H. E., Balk Aggie H. M. M., Roodnat Joke I., Holweg C??cile T. J., Baan Carla C., van Domburg Ron T., Weimar Willem, The Impact of Transforming Growth Factor-??1 Gene Polymorphism on End-Stage Renal Failure After Heart Transplantation : , 10.1097/01.tp.0000250360.78553.5e
  125. Matas Arthur J., Chronic Progressive Calcineurin Nephrotoxicity: An Overstated Concept : Chronic Calcineurin Nephrotoxicity, 10.1111/j.1600-6143.2011.03505.x
  126. Chapman J R, Chronic Calcineurin Inhibitor Use Is Nephrotoxic, 10.1038/clpt.2011.117
  127. Einecke G., Sis B., Reeve J., Mengel M., Campbell P. M., Hidalgo L. G., Kaplan B., Halloran P. F., Antibody-Mediated Microcirculation Injury Is the Major Cause of Late Kidney Transplant Failure, 10.1111/j.1600-6143.2009.02799.x
  128. McGuire Brendan M., Julian Bruce A., Bynon J. Steve, Cook William J., King Steven J., Curtis John J., Accortt Neil A., Eckhoff Devin E., Brief Communication: Glomerulonephritis in Patients with Hepatitis C Cirrhosis Undergoing Liver Transplantation, 10.7326/0003-4819-144-10-200605160-00007
  129. van Slambrouck Charles M., Salem Fadi, Meehan Shane M., Chang Anthony, Bile cast nephropathy is a common pathologic finding for kidney injury associated with severe liver dysfunction, 10.1038/ki.2013.78
  130. Snanoudj R., Royal V., Elie C., Rabant M., Girardin C., Morelon E., Kreis H., Fournet J.-C., Noël L.-H., Legendre C., Specificity of Histological Markers of Long-Term CNI Nephrotoxicity in Kidney-Transplant Recipients Under Low-Dose Cyclosporine Therapy : Histological Signs of CNI Toxicity, 10.1111/j.1600-6143.2011.03718.x
  131. Yates C. J., Fourlanos S., Hjelmesaeth J., Colman P. G., Cohney S. J., New-Onset Diabetes After Kidney Transplantation-Changes and Challenges : NODAT: Changes and Challenges, 10.1111/j.1600-6143.2011.03855.x
  132. Webster A. C, Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data, 10.1136/bmj.38569.471007.ae
  133. Numakura Kazuyuki, Satoh Shigeru, Tsuchiya Norihiko, Horikawa Yohei, Inoue Takamitsu, Kakinuma Hideaki, Matsuura Shinobu, Saito Mitsuru, Tada Hitoshi, Suzuki Toshio, Habuchi Tomonori, Clinical and Genetic Risk Factors for Posttransplant Diabetes Mellitus in Adult Renal Transplant Recipients Treated with Tacrolimus : , 10.1097/01.tp.0000181142.82649.e3
  134. Bamoulid J., IL-6 Promoter Polymorphism -174 Is Associated with New-Onset Diabetes after Transplantation, 10.1681/asn.2006010066
  135. Kang E. S., Kim M. S., Kim Y. S., Hur K. Y., Han S. J., Nam C. M., Ahn C. W., Cha B. S., Kim S. I., Lee H. C., A Variant of the Transcription Factor 7-Like 2 (TCF7L2) Gene and the Risk of Posttransplantation Diabetes Mellitus in Renal Allograft Recipients, 10.2337/dc07-1005
  136. Kang E. S., Kim M. S., Kim Y. S., Kim C. H., Han S. J., Chun S. W., Hur K. Y., Nam C. M., Ahn C. W., Cha B. S., Kim S. I., Lee H. C., A Polymorphism in the Zinc Transporter Gene SLC30A8 Confers Resistance Against Posttransplantation Diabetes Mellitus in Renal Allograft Recipients, 10.2337/db07-0761
  137. Ghisdal L., Baron C., Le Meur Y., Lionet A., Halimi J.-M., Rerolle J.-P., Glowacki F., Lebranchu Y., Drouet M., Noel C., El Housni H., Cochaux P., Wissing K. M., Abramowicz D., Abramowicz M., TCF7L2 Polymorphism Associates with New-Onset Diabetes after Transplantation, 10.1681/asn.2008121314
  138. Yang Jaewook, Hutchinson Ian I., Shah Tariq, Min David I., Genetic and Clinical Risk Factors of New-Onset Diabetes After Transplantation in Hispanic Kidney Transplant Recipients : , 10.1097/tp.0b013e31821620f9
  139. Chen Yan, Sampaio Marcelo S., Yang Jae Wook, Min David, Hutchinson Ian V., Genetic Polymorphisms of the Transcription Factor NFATc4 and Development of New-Onset Diabetes After Transplantation in Hispanic Kidney Transplant Recipients : , 10.1097/tp.0b013e31823f7f26
  140. Elens L, Sombogaard F, Hesselink DA, et al. Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-α are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus. Pharmacogenet Genom. Epub 2013 Oct 9. doi: 10.1097/FPC0000000000000001 .
  141. Tavira Beatriz, Coto Eliecer, Torres Armando, Díaz-Corte Carmen, Díaz-Molina Beatriz, Ortega Francisco, Arias Manuel, Díaz Juan M., Selgas Rafael, López-Larrea Carlos, Ruiz-Ortega Marta, Ortiz Alberto, González Elena, Campistol Josep M., Alvarez Victoria, Association between a common KCNJ11 polymorphism (rs5219) and new-onset posttransplant diabetes in patients treated with Tacrolimus, 10.1016/j.ymgme.2011.12.020
  142. Kang Eun Seok, Kim Myoung Soo, Kim Chul Hoon, Nam Chung Mo, Han Seung Jin, Hur Kyu Yeon, Ahn Chul Woo, Cha Bong Soo, Kim Soon Il, Lee Hyun Chul, Kim Yu Seun, Association of Common Type 2 Diabetes Risk Gene Variants and Posttransplantation Diabetes Mellitus in Renal Allograft Recipients in Korea : , 10.1097/tp.0b013e3181b29c41
  143. Kang Eun Seok, Magkos Faidon, Kim Beom Seok, Zhai Rihong, Su Li, Kim Yu Seun, Christiani David C., Lee Hyun Chul, Mantzoros Christos S., Variants of the Adiponectin and Adiponectin Receptor-1 Genes and Posttransplantation Diabetes Mellitus in Renal Allograft Recipients, 10.1210/jc.2011-1796
  144. Vincenti F., Charpentier B., Vanrenterghem Y., Rostaing L., Bresnahan B., Darji P., Massari P., Mondragon-Ramirez G. A, Agarwal M., Di Russo G., Lin C.-S., Garg P., Larsen C. P., A Phase III Study of Belatacept-based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study), 10.1111/j.1600-6143.2009.03005.x
  145. Bechstein Wolf O., Neurotoxicity of calcineurin inhibitors: impact and clinical management, 10.1111/j.1432-2277.2000.tb01004.x
  146. Wijdicks E, Neurotoxicity of immunosuppressive drugs, 10.1053/jlts.2001.27475
  147. Böttiger, Brattström, Tydén, Säwe, Groth, Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients : Short report, 10.1046/j.1365-2125.1999.00007.x
  148. Ekberg Henrik, Tedesco-Silva Helio, Demirbas Alper, Vítko Štefan, Nashan Björn, Gürkan Alp, Margreiter Raimund, Hugo Christian, Grinyó Josep M., Frei Ulrich, Vanrenterghem Yves, Daloze Pierre, Halloran Philip F., Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation, 10.1056/nejmoa067411
  149. Vizzini Giovanni, Asaro Monica, Miraglia Roberto, Gruttadauria Salvatore, Filì Daniela, D'Antoni Adele, Petridis Ioannis, Marrone Gianluca, Pagano Duilio, Gridelli Bruno, Changing picture of central nervous system complications in liver transplant recipients, 10.1002/lt.22383
  150. Tan Timothy C., Robinson Phillip J., Mechanisms of calcineurin inhibitor-induced neurotoxicity, 10.1016/j.trre.2006.02.005
  151. Cordon-Cardo C., O'Brien J. P., Casals D., Rittman-Grauer L., Biedler J. L., Melamed M. R., Bertino J. R., Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites., 10.1073/pnas.86.2.695
  152. Thiebaut F, Tsuruo T, Hamada H, Gottesman M M, Pastan I, Willingham M C, Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein., 10.1177/37.2.2463300
  153. Schinkel A H, Wagenaar E, van Deemter L, Mol C A, Borst P, Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A., 10.1172/jci118214
  154. Yokogawa Koichi, Takahashi Megumi, Tamai Ikumi, Konishi Hiroko, Nomura Masaaki, Moritani Shuzo, Miyamoto Ken‐ichi, Tsuji Akira, 10.1023/a:1018993312773
  155. Steiner Joseph P., Dawson Ted M., Fotuhi Majid, Glatt Charles E., Snowman Adele M., Cohen Noam, Snyder Solomon H., High brain densities of the immunophilin FKBP colocalized with calcineurin, 10.1038/358584a0
  156. Kaczmarek Ingo, Groetzner Jan, Meiser Bruno, Mueller Markus, Landwehr Peter, Ueberfuhr Peter, Bruning Roland, Reichart Bruno, Impairment of the blood-brain barrier can result in tacrolimus-induced reversible leucoencephalopathy following heart transplantation, 10.1034/j.1399-0012.2003.00071.x
  157. Yamauchi Atsushi, Ieiri Ichiro, Kataoka Yasufumi, Tanabe Mizuho, Nishizaki Takashi, Oishi Ryozo, Higuchi Shun, Otsubo Kenji, Sugimachi Keizo, Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene : , 10.1097/00007890-200208270-00024
  158. Yanagimachi Masakatsu, Naruto Takuya, Tanoshima Reo, Kato Hiromi, Yokosuka Tomoko, Kajiwara Ryosuke, Fujii Hisaki, Tanaka Fumiko, Goto Hiroaki, Yagihashi Tatsuhiko, Kosaki Kenjiro, Yokota Shumpei, Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor-related neurotoxicity after hematopoietic stem cell transplantation : CYP3A5 and ABCB1 with CNI neurotoxicity, 10.1111/j.1399-0012.2009.01181.x
  159. Arnold R., Pussell B. A., Pianta T. J., Lin C. S.-Y., Kiernan M. C., Krishnan A. V., Association Between Calcineurin Inhibitor Treatment and Peripheral Nerve Dysfunction in Renal Transplant Recipients : Nerve Function After Renal Transplantation, 10.1111/ajt.12324
  160. Hoorn Ewout J, Walsh Stephen B, McCormick James A, Fürstenberg Antje, Yang Chao-Ling, Roeschel Tom, Paliege Alexander, Howie Alexander J, Conley James, Bachmann Sebastian, Unwin Robert J, Ellison David H, The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension, 10.1038/nm.2497
  161. Bochud Murielle, Bovet Pascal, Burnier Michel, Eap Chin B, CYP3A5andABCB1genes and hypertension, 10.2217/14622416.10.3.477
  162. Ferraresso Mariano, Turolo Stefano, Ghio Luciana, Tirelli Amedea S., Belingheri Mirco, Villa Roberta, Groppali Elena, Edefonti Alberto, Association Between CYP3A5 Polymorphisms and Blood Pressure in Kidney Transplant Recipients Receiving Calcineurin Inhibitors, 10.3109/10641963.2011.561896
  163. Kreutz Reinhold, Z??rcher Heiko, Kain Silke, Martus Peter, Offermann Gerd, Beige Joachim, The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients : , 10.1097/00008571-200410000-00004
  164. Torio A., Auyanet I., Montes-Ares O., Guerra R.M., Fernandez E.J., Perez M.A., Ramirez A., Checa M.D., Effect of CYP3A5*1/*3 Polymorphism on Blood Pressure in Renal Transplant Recipients, 10.1016/j.transproceed.2012.09.047
  165. Li J-L, Wang X-D, Chen S-Y, Liu L-S, Fu Q, Chen X, Teng L-C, Wang C-X, Huang M, Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective, 10.1038/tpj.2010.42
  166. Chen Si-Yang, Li Jia-Li, Meng Fan-Hang, Wang Xue-Ding, Liu Tao, Li Jun, Liu Long-Shan, Fu Qian, Huang Min, Wang Chang-Xi, Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism - a prospective, randomized, controlled study, 10.1111/ctr.12101
  167. Hooper David K., Fukuda Tsuyoshi, Gardiner Rhonda, Logan Barbara, Roy-Chaudhury Ashwini, Kirby Cassie L., Vinks Alexander A., Goebel Jens, Risk of Tacrolimus Toxicity in CYP3A5 Nonexpressors Treated With Intravenous Nicardipine After Kidney Transplantation : , 10.1097/tp.0b013e318247a6c7
  168. Moreton M., CYP3A5 Genotype Does Not Influence the Blood Concentration of Tacrolimus Measured with the Abbott Immunoassay, 10.1373/clinchem.2005.056895
  169. Yoon Se-Hee, Cho Jang-Hee, Kwon Owen, Choi Ji-Young, Park Sun-Hee, Kim Yong-Lim, Yoon Young-Ran, Won Dong-Il, Kim Chan-Duck, CYP3A and ABCB1 Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Tacrolimus and Its Metabolites (M-I and M-III) : , 10.1097/tp.0b013e31827eef57
  170. Capron Arnaud, Musuamba Flora, Latinne Dominique, Mourad Michel, Lerut Jan, Haufroid Vincent, Wallemacq Pierre E, Validation of a Liquid Chromatography-Mass Spectrometric Assay for Tacrolimus in Peripheral Blood Mononuclear Cells : , 10.1097/ftd.0b013e3181905aaa
  171. Capron Arnaud, Lerut Jan, Latinne Dominique, Rahier Jacques, Haufroid Vincent, Wallemacq Pierre, Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: preliminary results of a prospective study : PBMCs tacrolimus levels and graft rejection, 10.1111/j.1432-2277.2011.01365.x
  172. Hitzl Monika, Drescher Siegfried, van der Kuip Heiko, Schäffeler Elke, Fischer Joachim, Schwab Matthias, Eichelbaum Michel, Fromm Martin F., The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells : , 10.1097/00008571-200106000-00003
  173. Crettol Séverine, Venetz Jean-Pierre, Fontana Massimiliano, Aubert John-David, Ansermot Nicolas, Fathi Marc, Pascual Manuel, Eap Chin B., Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients : , 10.1097/fpc.0b013e3282f7046f
  174. Capron Arnaud, Mourad Michel, De Meyer Martine, De Pauw Luc, Eddour Djamila Chaib, Latinne Dominique, Elens Laure, Haufroid Vincent, Wallemacq Pierre, CYP3A5andABCB1polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation, 10.2217/pgs.10.43
  175. Llaudó Inés, Colom Helena, Giménez-Bonafé Pepita, Torras Joan, Caldés Anna, Sarrias Maria, Cruzado Josep Mª, Oppenheimer Federico, Sánchez-Plumed Jaime, Gentil Miguel Ángel, Ekberg Henrik, Grinyó Josep Mª, Lloberas Núria, Do drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the symphony study, 10.1111/tri.12018
  176. Vafadari Ramin, Bouamar Rachida, Hesselink Dennis A., Kraaijeveld Rens, van Schaik Ron H. N., Weimar Willem, Baan Carla C., van Gelder Teun, Genetic Polymorphisms in ABCB1 Influence the Pharmacodynamics of Tacrolimus : , 10.1097/ftd.0b013e31828c1581
  177. Capron Arnaud, Lerut Jan, Verbaandert Catherine, Mathys Jules, Ciccarelli Olga, Vanbinst Roger, Roggen Francine, De Reyck Chantal, Lemaire Julien, Wallemacq Pierre E, Validation of a Liquid Chromatography-Mass Spectrometric Assay for Tacrolimus in Liver Biopsies After Hepatic Transplantation: Correlation With Histopathologic Staging of Rejection : , 10.1097/ftd.0b013e31805c73f1
  178. Noll BD, Coller JK, Somogyi AA, et al. Validation of an LC-MS/MS method to measure tacrolimus in rat kidney and liver tissue and its application to human kidney biopsies. Ther Drug Monit. 2013;35:617–23.
  179. Elens Laure, Capron Arnaud, Kerckhove Valérie Van, Lerut Jan, Mourad Michel, Lison Dominique, Wallemacq Pierre, Haufroid Vincent, 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation : , 10.1097/fpc.0b013e3282e9a533
  180. Zahir Hamim, McCaughan Geoffrey, Gleeson Margaret, Nand Romina A., McLachlan Andrew J., Changes in Tacrolimus Distribution in Blood and Plasma Protein Binding Following Liver Transplantation : , 10.1097/00007691-200410000-00008
  181. Weinshilboum Richard, Inheritance and Drug Response, 10.1056/nejmra020021
  182. Mallal Simon, Phillips Elizabeth, Carosi Giampiero, Molina Jean-Michel, Workman Cassy, Tomažič Janez, Jägel-Guedes Eva, Rugina Sorin, Kozyrev Oleg, Cid Juan Flores, Hay Phillip, Nolan David, Hughes Sara, Hughes Arlene, Ryan Susanna, Fitch Nicholas, Thorborn Daren, Benbow Alastair, HLA-B*5701 Screening for Hypersensitivity to Abacavir, 10.1056/nejmoa0706135
  183. Chen Pei, Lin Juei-Jueng, Lu Chin-Song, Ong Cheung-Ter, Hsieh Peiyuan F., Yang Chih-Chao, Tai Chih-Ta, Wu Shey-Lin, Lu Cheng-Hsien, Hsu Yung-Chu, Yu Hsiang-Yu, Ro Long-Sun, Lu Chung-Ta, Chu Chun-Che, Tsai Jing-Jane, Su Yu-Hsiang, Lan Sheng-Hsing, Sung Sheng-Feng, Lin Shu-Yi, Chuang Hui-Ping, Huang Li-Chen, Chen Ying-Ju, Tsai Pei-Joung, Liao Hung-Ting, Lin Yu-Hsuan, Chen Chien-Hsiun, Chung Wen-Hung, Hung Shuen-Iu, Wu Jer-Yuarn, Chang Chi-Feng, Chen Luke, Chen Yuan-Tsong, Shen Chen-Yang, Carbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in Taiwan, 10.1056/nejmoa1009717
  184. McCormack Mark, Alfirevic Ana, Bourgeois Stephane, Farrell John J., Kasperavičiūtė Dalia, Carrington Mary, Sills Graeme J., Marson Tony, Jia Xiaoming, de Bakker Paul I.W., Chinthapalli Krishna, Molokhia Mariam, Johnson Michael R., O'Connor Gerard D., Chaila Elijah, Alhusaini Saud, Shianna Kevin V., Radtke Rodney A., Heinzen Erin L., Walley Nicole, Pandolfo Massimo, Pichler Werner, Park B. Kevin, Depondt Chantal, Sisodiya Sanjay M., Goldstein David B., Deloukas Panos, Delanty Norman, Cavalleri Gianpiero L., Pirmohamed Munir, HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans, 10.1056/nejmoa1013297
Référence bibliographique Hesselink, Dennis A. ; Bouamar, Rachida ; Elens, Laure ; Van Schaik, Ron H. N. ; Van Gelder, Teun. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. In: Clinical Pharmacokinetics, Vol. 53, no. 2, p. 123-139 (2014)
Permalien http://hdl.handle.net/2078.1/160495